118 related articles for article (PubMed ID: 4416021)
1. Synthesis and metabolic behavior of the suggested active species of isophosphamide having cytostatic activity.
Takamizawa A; Matsumoto S; Iwata T; Tochino Y; Katagiri K
J Med Chem; 1974 Nov; 17(11):1237-9. PubMed ID: 4416021
[No Abstract] [Full Text] [Related]
2. Metabolism of iphosphamide (2-(2-chloroethylamino)-3-(2-chloroethyl)tetrahydro-2H-1,3,2-oxazaphosphorine 2-oxide) and production of a toxic iphosphamide metabolite.
Hill DL; Laster WR; Kirk MC; el-Dareer S; Struck RF
Cancer Res; 1973 May; 33(5):1016-22. PubMed ID: 4703116
[No Abstract] [Full Text] [Related]
3. Clinical pharmacology of isophosphamide.
Creaven PJ; Allen LM; Alford DA; Cohen MH
Clin Pharmacol Ther; 1974 Jul; 16(1):77-86. PubMed ID: 4602057
[No Abstract] [Full Text] [Related]
4. Activation of the antineoplastic drug isophosphamide by rat liver microsomes.
Allen LM; Creaven PJ
J Pharm Pharmacol; 1972 Jul; 24(7):585-6. PubMed ID: 4403857
[No Abstract] [Full Text] [Related]
5. Teratogenicity and neonatal toxicity of ifosfamide in mice.
Bus JS; Gibson JE; Reinke DA
Proc Soc Exp Biol Med; 1973 Sep; 143(4):965-70. PubMed ID: 4743716
[No Abstract] [Full Text] [Related]
6. Protection with N-acetyl-L-cysteine (NSC-111180) against isophosphamide (NSC-109724) toxicity and enhancement of therapeutic effect in early murine L1210 leukemia.
Kline I; Gang M; Woodman RJ; Cysyk RL; Venditti JM
Cancer Chemother Rep; 1973; 57(3):299-304. PubMed ID: 4751256
[No Abstract] [Full Text] [Related]
7. [Clinical evaluation of ifosfamide in the treatment of malignant neoplasms].
Czownicki Z; Utracka B; Till A; Styrna M
Nowotwory; 1973; 23(3):285-90. PubMed ID: 4757587
[No Abstract] [Full Text] [Related]
8. Renal dysfunction after treatment with isophosphamide (NSC-109724).
DeFronzo RA; Abeloff M; Braine H; Humphrey RL; Davis PJ
Cancer Chemother Rep; 1974; 58(3):375-82. PubMed ID: 4842666
[No Abstract] [Full Text] [Related]
9. [Activation of ifosfamide in man and animal].
Brock N; Hoefer-Janker H; Hohorst HJ; Scheef W; Schneider B; Wolf HC
Arzneimittelforschung; 1973 Jan; 23(1):1-14. PubMed ID: 4353374
[No Abstract] [Full Text] [Related]
10. Isophosphamide as a new acrolein-producing antineoplastic isomer of cyclophosphamide.
Alarcon RA; Meienhofer J; Atherton E
Cancer Res; 1972 Nov; 32(11):2519-23. PubMed ID: 5082597
[No Abstract] [Full Text] [Related]
11. Some studies of the active intermediates formed in the microsomal metabolism of cyclophosphamide and isophosphamide.
Connors TA; Cox PJ; Farmer PB; Foster AB; Jarman M
Biochem Pharmacol; 1974 Jan; 23(1):115-29. PubMed ID: 4811053
[No Abstract] [Full Text] [Related]
12. [Pharmacologic studies with trophosphamide (Ixoten), a new oxazaphosphorineoxide].
Brock N
Med Monatsschr; 1973 Sep; 27(9):390-4. PubMed ID: 4768197
[No Abstract] [Full Text] [Related]
13. In vitro activation of isophosphamide (NSC-109724), a new oxazaphosphorine, by rat liver microsomes.
Allen LM; Creaven PJ
Cancer Chemother Rep; 1972 Oct; 56(5):603-10. PubMed ID: 4405717
[No Abstract] [Full Text] [Related]
14. Phase II clinical trial of isophosphamide (NSC-109724) in patients with advances breast cancer.
Ahmann DL; Bisel HF; Hahn RG
Cancer Chemother Rep; 1974; 58(6):861-5. PubMed ID: 4615785
[No Abstract] [Full Text] [Related]
15. Potentially useful combinations of chemotherapy detected in mouse tumor systems.
Kline I
Cancer Chemother Rep 2; 1974 Mar; 4(1):33-43. PubMed ID: 4133187
[No Abstract] [Full Text] [Related]
16. Clinical trial of isophosphamide (NSC-109724)--results and side effects.
Bremner DN; McCormick JS; Thomson JW
Cancer Chemother Rep; 1974; 58(6):889-93. PubMed ID: 4614898
[No Abstract] [Full Text] [Related]
17. [Comparative study of cyclophosphamide, ifosfamide and trofosfamide on Walker-256 carcinosarcoma in embryonated chicken eggs].
Norpoth K; Witting U; Rauen HM
Arzneimittelforschung; 1974 Jan; 24(1):86-9. PubMed ID: 4406116
[No Abstract] [Full Text] [Related]
18. Synthesis and pharmacological screening of 1-chloro-3-(2-propynyloxy)-2-propanols and 2-((2-propynyloxy)methyl)oxiranes.
Fugitt RB; Wu GS; Martinelli LC
J Pharm Sci; 1973 Nov; 62(11):1894-6. PubMed ID: 4758098
[No Abstract] [Full Text] [Related]
19. 1,3,2-dioxaphosphorinane 2-oxides. IV. Preparation of some 2-substituted-5-carbomethoxy-5-methyl-1,3,2-dioxaphosphorinane 2-oxides as potential antitumor agents.
Billman JH; Roehrig GR
J Pharm Sci; 1970 Jun; 59(6):861-3. PubMed ID: 5423097
[No Abstract] [Full Text] [Related]
20. Pharmacological studies with alkylsulfonyloxyalkyl substituted and chloroethyl substituted oxazaphosphorine-2-oxides. 1. Communication: relationship between chemical structure and pharmacological action.
Brock N; Kuhlmann J
Arzneimittelforschung; 1974 Aug; 24(8):1139-49. PubMed ID: 4371234
[No Abstract] [Full Text] [Related]
[Next] [New Search]
